Boehringer Elecsys 1998 gross sales projected at $150 mil. -- Igen breach of contract lawsuit.
This article was originally published in The Gray Sheet
Executive Summary
IGEN SEEKS TERMINATION OF BOEHRINGER ECL LICENSING AGREEMENT in a complaint filed Sept. 15 with the Circuit Court for Montgomery County, Maryland. Igen alleges that Boehringer Mannheim has failed to meet its royalty obligations and violated other terms of a 1992 license and technology development pact. The agreement gave Boehringer exclusive rights to immunoassay applications of Igen's Origen electrochemiluminescence technology and semi-exclusive rights to ECL for use in nucleic acid-probe products.
You may also be interested in...
Roche Purchase of Igen Resolves Licensing Dispute, Preserves Technology
Roche Diagnostics will retain roughly $400 mil. in annual revenues through the $1.4 bil. acquisition of Origen electrochemilumunescence technology licensor Igen International
Roche Purchase of Igen Resolves Licensing Dispute, Preserves Technology
Roche Diagnostics will retain roughly $400 mil. in annual revenues through the $1.4 bil. acquisition of Origen electrochemilumunescence technology licensor Igen International
Roche Elecsys Upgrades Go To Igen, But $486 Mil. In Penalties Are Vacated
The path is clear for Igen to renegotiate a licensing and development deal with Roche Diagnostics, following a federal appeals court ruling July 9, enabling Igen to terminate its previous agreement